Validity of the PROMIS-29 in a large Australian cohort of patients with systemic sclerosis

Marie I Jouen F Hellot MF Levesque H Anticardiolipin and anti-beta2 glycoprotein I antibodies and lupus-like anticoagulant: prevalence and significance in systemic sclerosis. Br J Dermatol 2008;158(1):141144

Thombs BD Taillefer SS Hudson M Baron M Depression in patients with systemic sclerosis: a systematic review of the evidence. Arthritis Rheum 2007;57(6):10891097

Poole JL Steen VD The use of the Health Assessment Questionnaire (HAQ) to determine physical disability in systemic sclerosis. Arthritis Care Res 1991;4(1):2731

Testa MA Simonson DC Assessment of quality-of-life outcomes. N Engl J Med 1996;334(13):835840

Johnson SR Glaman DD Schentag CT Lee P Quality of life and functional status in systemic sclerosis compared to other rheumatic diseases. J Rheumatol 2006;33(6):11171122

Smyth AE MacGregor AJ Mukerjee D Brough GM Black CM Denton CP A cross-sectional comparison of three self-reported functional indices in scleroderma. Rheumatology (Oxford) 2003;42(6):732738

Cella D Yount S Rothrock N et al. PROMIS Cooperative Group. The Patient-Reported Outcomes Measurement Information System (PROMIS): progress of an NIH Roadmap cooperative group during its first two years. Med Care 2007;455(Suppl 1):S3S11

Reeve BB Teresi JA Overview to the two-part series: measurement equivalence of the Patient Reported Outcomes Measurement Information System® (PROMIS®) short forms. Psychological Test and Assessment Modeling 2016;58(1):3135 Available from http://www.psychologie-aktuell.com/fileadmin/download/ptam/1-2016_20163003/03_Reeve.pdf. Accessed May 18, 2017.

PROMIS Patient-Reported Outcomes Measurement Information System. Available from: http://www.nihpromis.org. Accessed May 18, 2017.

Khanna D Maranian P Rothrock N et al. Feasibility and construct validity of PROMIS and “legacy” instruments in an academic scleroderma clinic. Value Health 2012;15(1):128134

Hinchcliff M Beaumont JL Thavarajah K et al. Validity of two new patient-reported outcome measures in systemic sclerosis: Patient-Reported Outcomes Measurement Information System 29-item Health Profile and Functional Assessment of Chronic Illness Therapy-Dyspnea short form. Arthritis Care Res (Hoboken) 2011;63(11):16201628

Masi AT Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980;23(5):581590

LeRoy EC Medsger TA Jr Criteria for the classification of early systemic sclerosis. J Rheumatol 2001;28(7):15731576

Ware JE Jr Sherbourne CD The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30(6):473483

Valentini G Bencivelli W Bombardieri S et al. European Scleroderma Study Group to define disease activity criteria for systemic sclerosis. III. Assessment of the construct validity of the preliminary activity criteria. Ann Rheum Dis 2003;62(9):901903

Pope J Measures of systemic sclerosis (scleroderma): Health Assessment Questionnaire (HAQ) and Scleroderma HAQ (SHAQ), physician- and patient-rated global assessments, Symptom Burden Index (SBI), University of California, Los Angeles, Scleroderma Clinical Trials Consortium Gastrointestinal Scale (UCLA SCTC GIT) 2.0, Baseline Dyspnea Index (BDI) and Transition Dyspnea Index (TDI) (Mahlers Index), Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR), and Raynauds Condition Score (RCS). Arthritis Care Res (Hoboken) 2011;63(S11)(Suppl 11):S98S111

Galiè N Humbert M Vachiery JL et al. 2015 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension. Rev Esp Cardiol (Engl Ed) 2016;69(2):177

Cronbach LJ Coefficient alpha and the internal structure of tests. Psychometrika 1951;16(3):297334

Müller‐Nordhorn J Assessing quality of life in clinical trials, 2nd ed. J Epidemiol Community Health 2006;60(9):822

Cohen J A power primer. Psychol Bull 1992;112(1):155159

Khanna D Clements PJ Postlethwaite AE Furst DE Does incorporation of aids and devices make a difference in the score of the health assessment questionnaire-disability index? Analysis from a scleroderma clinical trial. J Rheumatol 2008;35(3):466468

Rothrock NE Hays RD Spritzer K Yount SE Riley W Cella D Relative to the general US population, chronic diseases are associated with poorer health-related quality of life as measured by the Patient-Reported Outcomes Measurement Information System (PROMIS). J Clin Epidemiol 2010;63(11):11951204

Hudson M Thombs BD Steele R Panopalis P Newton E Baron M Canadian Scleroderma Research Group. Quality of life in patients with systemic sclerosis compared to the general population and patients with other chronic conditions. J Rheumatol 2009;36(4):768772

Khanna D Clements PJ Furst DE et al. Scleroderma Lung Study Group. Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung Study. Arthritis Rheum 2005;52(2):592600

Farivar SS Cunningham WE Hays RD Correlated physical and mental health summary scores for the SF-36 and SF-12 Health Survey, V.I. Health Qual Life Outcomes 2007;5(1):54

Montazeri A Quality of life data as prognostic indicators of survival in cancer patients: an overview of the literature from 1982 to 2008. Health Qual Life Outcomes 2009;7(1):102